<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05610319</url>
  </required_header>
  <id_info>
    <org_study_id>2022-01</org_study_id>
    <secondary_id>MR44143</secondary_id>
    <nct_id>NCT05610319</nct_id>
  </id_info>
  <brief_title>Treat &amp; Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial</brief_title>
  <acronym>INSITE-DME</acronym>
  <official_title>Treat &amp; Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess a pragmatic, treat and extend regimen of faricimab against the&#xD;
      standard of a fixed dosing regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2023</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two-armed, parallel, non-inferiority randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Best Corrected Visual Acuity</measure>
    <time_frame>Baseline to Week 100</time_frame>
    <description>Change in best corrected visual acuity (3.9 letter non-inferiority margin)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in Diabetic Retinopathy Severity Score</measure>
    <time_frame>Baseline to Week 100</time_frame>
    <description>A 2-step improvement in diabetic retinopathy severity score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in Diabetic Retinopathy Severity Score</measure>
    <time_frame>Baseline to Week 100</time_frame>
    <description>A 3-step improvement in diabetic retinopathy severity score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Central Subfield Thickness</measure>
    <time_frame>Baseline to Week 100</time_frame>
    <description>Change in central subfield thickness on OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vision Related Quality of Life</measure>
    <time_frame>Baseline to Week 100</time_frame>
    <description>Change in vision-related quality of life (VFQ-25)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Letters of Vision</measure>
    <time_frame>Baseline to Week 100</time_frame>
    <description>Gaining or losing ≥5, ≥10, or ≥15 letters of vision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Diabetic Macular Edema</measure>
    <time_frame>Week 100</time_frame>
    <description>Absence of diabetic macular edema in the study eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Intraretinal Fluid (IRF)</measure>
    <time_frame>Week 100</time_frame>
    <description>Absence of intraretinal fluid (IRF) in the study eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosing Interval</measure>
    <time_frame>Week 100</time_frame>
    <description>Dosing interval at week 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Safety Outcomes</measure>
    <time_frame>Baseline to Week 100</time_frame>
    <description>Safety outcomes (ocular and systemic AEs and SAEs)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">446</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Treat and Extend</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the T&amp;E Arm will initially receive 6 milligrams (mg) faricimab intravitreal (IVT) injections monthly (28d +/-7 days), with treatment intervals increased/extended, reduced, or maintained based on CST assessments, until week 100.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control/Usual Care Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants in the control arm will receive 6 milligrams (mg) faricimab intravitreal (IVT) injections monthly (28d +/-7 days), for 6 treatments. Afterwards, participants will continue to receive 6mg faricimab IVT every 8 weeks until week 100.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faricimab</intervention_name>
    <description>Faricimab will be administered via intravitreal injection.</description>
    <arm_group_label>Control/Usual Care Arm</arm_group_label>
    <arm_group_label>Treat and Extend</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Diagnosis of diabetes mellitus (type 1 or type 2).&#xD;
&#xD;
          3. Macular thickening secondary to DME (CI-DME) involving the center of the fovea on&#xD;
             Optical Coherence Tomography - Central subfield thickness (CST) ≥ 325 μm on Spectralis&#xD;
             at screening.***&#xD;
&#xD;
          4. Visual impairment due to DME, with best corrected visual acuity of 80 to 20 letters&#xD;
             (Snellen VA 20/25 - 20/400).&#xD;
&#xD;
          5. Media clarity, pupillary dilation, and individual cooperation sufficient for adequate&#xD;
             OCT and fundus photographs.&#xD;
&#xD;
          6. Hemoglobin A1c must be &lt;10% within 2 months prior to 1st study treatment.&#xD;
&#xD;
          7. Provide signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active or history of ocular inflammation or suspected/active ocular infection in&#xD;
             either eye.&#xD;
&#xD;
          2. High-risk proliferative diabetic retinopathy in the study eye.**&#xD;
&#xD;
          3. Tractional retinal detachment, preretinal fibrosis or visually significant epiretinal&#xD;
             membrane involving the macula.&#xD;
&#xD;
          4. Uncontrolled glaucoma (intraocular pressure &gt;30 with or without medications).&#xD;
&#xD;
          5. Any intravitreal, periocular or implant corticosteroids within 26 weeks (6 months)&#xD;
             before day 1 or any use of Iluvien implants.&#xD;
&#xD;
          6. Treatment with Panretinal photocoagulation (PRP) within 12 weeks before day 1.&#xD;
&#xD;
          7. Treatment with macular laser.&#xD;
&#xD;
          8. Any cataract surgery or any other intraocular surgery within 12 weeks before day 1.&#xD;
&#xD;
          9. Macular edema in study eye due to a cause other than DME.&#xD;
&#xD;
         10. If clinical exam and/or OCT and/or wide-field fluorescein angiography (WF-FA) suggest&#xD;
             that (a) macular edema is considered to be related to ocular surgery such as cataract&#xD;
             extraction or (b) if primary cause for macular edema is vitreoretinal interface&#xD;
             abnormalities (e.g. a taut posterior hyaloid or epiretinal membrane).&#xD;
&#xD;
         11. Any ocular condition is present such that visual acuity loss would not improve from&#xD;
             resolution of macular edema in opinion of the investigator (e.g. foveal atrophy,&#xD;
             pigment abnormalities, dense subfoveal hard exudates, nonretinal condition)&#xD;
&#xD;
         12. Any history of ocular conditions that might affect macular edema (e.g. vein occlusion,&#xD;
             idiopathic or infectious or non-infectious uveitis, ocular inflammatory disease,&#xD;
             neovascular glaucoma etc.)&#xD;
&#xD;
         13. Women of child-bearing potential who are lactating, pregnant, or intending to become&#xD;
             pregnant within the next 100 weeks.&#xD;
&#xD;
         14. Current or anticipated incarceration.&#xD;
&#xD;
         15. Terminal illness with expected survival less than 100 weeks.&#xD;
&#xD;
         16. Known hypersensitivity to faricimab or any of the excipients in the faricimab&#xD;
             injection.&#xD;
&#xD;
         17. Currently enrolled in a study that does not permit co-enrollment.&#xD;
&#xD;
         18. Unable to obtain informed consent due to language or other operational barriers.&#xD;
&#xD;
         19. Anticipated problems, in the judgment of the site investigator, maintaining compliance&#xD;
             with the protocol, including attending study visits, completing assessments or&#xD;
             procedures.&#xD;
&#xD;
         20. Prior enrollment in this trial.&#xD;
&#xD;
         21. Other reason to exclude the patient, as approved by the sponsor and site investigator.&#xD;
&#xD;
         22. Previous treatment with anti-VEGF and:&#xD;
&#xD;
               -  &lt;12 weeks prior to day 1 (washout period).*or,&#xD;
&#xD;
               -  Diagnosis of DME is &gt; 2 years of enrollment or,&#xD;
&#xD;
               -  Do not have a demonstrated response to anti-VEGF treatment based on clinical&#xD;
                  discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Varun Chaudhary, MD, FRCS(C)</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gina Del Fabbro, BPH</last_name>
    <phone>905-525-9140</phone>
    <phone_ext>21852</phone_ext>
    <email>delfabbg@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Carruthers</last_name>
    <phone>905-327-5635</phone>
    <phone_ext>24392</phone_ext>
    <email>carrutj@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Research Institute of St. Joe's Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8G 5E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorell Gantioqui</last_name>
      <email>gantioj@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Eugene Wu</last_name>
      <email>wue9@mcmaster.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Varun Chaudhary, MD, FRCS(C)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Institute of Ottawa</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2B 7E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon MacDonald</last_name>
    </contact>
    <contact_backup>
      <last_name>Kayleigh Corbet</last_name>
    </contact_backup>
    <investigator>
      <last_name>Raman Tuli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>November 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 2, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2022</study_first_posted>
  <last_update_submitted>May 4, 2023</last_update_submitted>
  <last_update_submitted_qc>May 4, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treat and Extend</keyword>
  <keyword>Faricimab</keyword>
  <keyword>Anti-VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

